Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced on Tuesday that Chairman, Chief Executive Officer, and Founder, Joel S. Marcus, was unanimously elected to the Board of Directors of the Foundation for the National Institutes of Health (FNIH). Among the board members' responsibilities are helping guide the FNIH's mission and purpose; ensuring effective organizational planning; ensuring adequate resources and managing them effectively; reviewing, monitoring, and strengthening the FNIH's programs and services; and enhancing the FNIH's public standing. Other board members include former Chairman and Chief Executive Officer of Glaxo Inc., Charles A. Sanders, M.D.; James H. Donovan, Partner at Goldman Sachs & Company; Freda C. Lewis-Hall, M.D., FAPA, Chief Medical Officer and Executive Vice President of Pfizer Inc.; Paul L. Herrling, Ph.D., Chairman of the Novartis Institute for Tropical Diseases; Steven M. Paul, M.D., former Executive Vice President of Science and Technology and President of the Lilly Research Laboratories of Eli Lilly and Company; and Ellen V. Sigal, Ph.D., Chairperson and Founder of Friends of Cancer Research. Mr. Marcus began his term May 16, 2012.
"The wealth of knowledge Joel possesses will be an asset to the FNIH," stated Charles A. Sanders, MD, Chairman of the FNIH. "He will diversify the knowledge base of our directors and makes a wonderful addition to our board."
"Joel has a long standing commitment to science and a deep understanding of what is needed to foster and encourage creativity and innovation in scientific research," noted Mrs. William McCormick Blair, Jr., FNIH board secretary.
"Having worked closely with a plethora of public and private entities within the broad and diverse life science community for nearly 30 years, I have personally witnessed the critical role that strategic funding for innovative research plays in the development of novel breakthrough discoveries that prevent illness, save lives, improve the quality of life, and significantly reduce the economic burden of disease on society," said Mr. Marcus. "As the global leader in cutting-edge life science research, our nation must continue its commitment to fund this mission-critical, world-class research engine, which is both enormously and positively impactful on human health as well as a major generator of high-quality jobs. I look forward to working alongside my colleagues as a board member of the FNIH to carry out this mission efficiently and effectively."
Mr. Marcus also serves on the boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Intra-Cellular Therapies, Inc., and Research!America.